Clinical trials for prion disease: difficult challenges, but hope for the future

Comment

Michael D Geschwind. Lancet Neurol. 2009 Apr.

. 2009 Apr;8(4):304-6.

doi: 10.1016/S1474-4422(09)70050-X. Epub 2009 Mar 9.

No abstract available

Figures

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.
Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J. Collinge J, et al. Lancet Neurol. 2009 Apr;8(4):334-44. doi: 10.1016/S1474-4422(09)70049-3. Epub 2009 Mar 9. Lancet Neurol. 2009. PMID: 19278902 Free PMC article. Clinical Trial.

1. Prusiner SB. Shattuck lecture—neurodegenerative diseases and prions. N Engl J Med. 2001;344:1516–26. - PubMed
1. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain. 2006;129:2241–65. - PubMed
1. Bone I. In: Intraventricular pentosan polysulfate in human prion diseases. A study of experience in the United Kingdom. Unit UKCS, editor. Edinburgh, UK: 2006. pp. 1–11.
1. Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacoptherapeutics for prion disease. Proc Natl Acad Sci USA. 2001;98:9836–41. - PMC - PubMed
1. Otto M, Cepek L, Ratzka P, et al. Efficacy of fl upirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004;62:714–18. - PubMed